
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3485978/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. Journal of Rheumatology, 2003, 30, 1385-6.	2.0	494
2	Safety and efficacy of vertebroplasty for acute painful osteoporotic fractures (VAPOUR): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet, The, 2016, 388, 1408-1416.	13.7	321
3	Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: A two-year prospective study (the DAMAGE study cohort). Arthritis and Rheumatism, 2006, 54, 1122-1131.	6.7	309
4	Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Annals of the Rheumatic Diseases, 2016, 75, 1065-1073.	0.9	225
5	The OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System (PsAMRIS): Definitions of Key Pathologies, Suggested MRI Sequences, and Preliminary Scoring System for PsA Hands. Journal of Rheumatology, 2009, 36, 1816-1824.	2.0	168
6	The OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging (MRI) Scoring System: Updated Recommendations by the OMERACT MRI in Arthritis Working Group. Journal of Rheumatology, 2017, 44, 1706-1712.	2.0	102
7	Synovitis and Osteitis Are Very Frequent in Rheumatoid Arthritis Clinical Remission: Results from an MRI Study of 294 Patients in Clinical Remission or Low Disease Activity State. Journal of Rheumatology, 2011, 38, 2039-2044.	2.0	101
8	Reducing Invasiveness, Duration, and Cost of Magnetic Resonance Imaging in Rheumatoid Arthritis by Omitting Intravenous Contrast Injection — Does It Change the Assessment of Inflammatory and Destructive Joint Changes by the OMERACT RAMRIS?. Journal of Rheumatology, 2009, 36, 1806-1810.	2.0	91
9	OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Exercise 3: an international multicenter reliability study using the RA-MRI Score. Journal of Rheumatology, 2003, 30, 1366-75.	2.0	91
10	Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Annals of the Rheumatic Diseases, 2017, 76, 694-700.	0.9	83
11	Computerized measurement of magnetic resonance imaging erosion volumes in patients with rheumatoid arthritis: A comparison with existing magnetic resonance imaging scoring systems and standard clinical outcome measures. Arthritis and Rheumatism, 2003, 48, 614-624.	6.7	73
12	Development and Preliminary Validation of a Magnetic Resonance Imaging Joint Space Narrowing Score for Use in Rheumatoid Arthritis: Potential Adjunct to the OMERACT RA MRI Scoring System. Journal of Rheumatology, 2011, 38, 2045-2050.	2.0	72
13	Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology, 2018, 57, 1253-1263.	1.9	72
14	OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Summary of OMERACT 6 MR Imaging Module. Journal of Rheumatology, 2003, 30, 1387-92.	2.0	72
15	Determining a Magnetic Resonance Imaging Inflammatory Activity Acceptable State Without Subsequent Radiographic Progression in Rheumatoid Arthritis: Results from a Followup MRI Study of 254 Patients in Clinical Remission or Low Disease Activity. Journal of Rheumatology, 2014, 41, 398-406.	2.0	71
16	The OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) Is Reliable and Sensitive to Change: Results from an OMERACT Workshop. Journal of Rheumatology, 2011, 38, 2034-2038.	2.0	66
17	Barriers to Optimal Disease Control for Rheumatoid Arthritis Patients With Moderate and High Disease Activity. Arthritis Care and Research, 2014, 66, 190-196.	3.4	56
18	Iterative Development and Reliability of the OMERACT Hand Osteoarthritis MRI Scoring System. Journal of Rheumatology, 2014, 41, 386-391.	2.0	55

#	Article	IF	CITATIONS
19	Validation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) for the Hand and Foot in a Randomized Placebo-controlled Trial. Journal of Rheumatology, 2015, 42, 2473-2479.	2.0	54
20	Whole-body Magnetic Resonance Imaging in Inflammatory Arthritis: Systematic Literature Review and First Steps Toward Standardization and an OMERACT Scoring System. Journal of Rheumatology, 2017, 44, 1699-1705.	2.0	48
21	The SMILE Study — Safety of Methotrexate in Combination with Leflunomide in Rheumatoid Arthritis. Journal of Rheumatology, 2013, 40, 228-235.	2.0	41
22	Developing a magnetic resonance imaging scoring system for peripheral psoriatic arthritis. Journal of Rheumatology, 2007, 34, 859-61.	2.0	39
23	The OMERACT-RAMRIS Rheumatoid Arthritis Magnetic Resonance Imaging Joint Space Narrowing Score: Intrareader and Interreader Reliability and Agreement with Computed Tomography and Conventional Radiography. Journal of Rheumatology, 2014, 41, 392-397.	2.0	38
24	The OMERACT MRI in Enthesitis Initiative: Definitions of Key Pathologies, Suggested MRI Sequences, and a Novel Heel Enthesitis Scoring System. Journal of Rheumatology, 2019, 46, 1232-1238.	2.0	37
25	Development and Validation of an OMERACT MRI Whole-Body Score for Inflammation in Peripheral Joints and Entheses in Inflammatory Arthritis (MRI-WIPE). Journal of Rheumatology, 2019, 46, 1215-1221.	2.0	35
26	No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients: results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial. Rheumatology, 2014, 53, 746-756.	1.9	34
27	The role of MRI in rheumatoid arthritis: research and clinical issues. Current Opinion in Rheumatology, 2009, 21, 95-101.	4.3	33
28	OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Exercise 5: an international multicenter reliability study using computerized MRI erosion volume measurements. Journal of Rheumatology, 2003, 30, 1380-4.	2.0	33
29	How Well Do Patients Understand Written Instructions?. Medicine (United States), 2014, 93, e129.	1.0	32
30	Testing an OMERACT MRI Scoring System for Peripheral Psoriatic Arthritis in Cross-sectional and Longitudinal Settings. Journal of Rheumatology, 2009, 36, 1811-1815.	2.0	29
31	Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib. RMD Open, 2019, 5, e000742.	3.8	28
32	Validation of the OMERACT Magnetic Resonance Imaging Joint Space Narrowing Score for the Wrist in a Multireader Longitudinal Trial. Journal of Rheumatology, 2015, 42, 2480-2485.	2.0	27
33	Documenting damage progression in a two-year longitudinal study of rheumatoid arthritis patients with established disease (the DAMAGE study cohort): Is there an advantage in the use of magnetic resonance imaging as compared with plain radiography?. Arthritis and Rheumatism, 2004, 50, 1383-1389.	6.7	26
34	The Longitudinal Reliability and Responsiveness of the OMERACT Hand Osteoarthritis Magnetic Resonance Imaging Scoring System (HOAMRIS). Journal of Rheumatology, 2015, 42, 2486-2491.	2.0	25
35	A multireader reliability study comparing conventional high-field magnetic resonance imaging with extremity low-field MRI in rheumatoid arthritis. Journal of Rheumatology, 2007, 34, 854-6.	2.0	25
36	Development and Validation of the OMERACT Rheumatoid Arthritis Magnetic Resonance Tenosynovitis Scoring System in a Multireader Exercise. Journal of Rheumatology, 2017, 44, 1688-1693.	2.0	23

#	Article	IF	CITATIONS
37	Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia. Clinical Rheumatology, 2020, 39, 2545-2551.	2.2	21
38	A retrospective review of the persistence on <scp>bDMARD</scp> s prescribed for the treatment of rheumatoid arthritis in the Australian population. International Journal of Rheumatic Diseases, 2018, 21, 1581-1590.	1.9	21
39	Training and calibration improve inter-reader reliability of joint damage assessment using magnetic resonance image scoring and computerized erosion volume measurement. Journal of Rheumatology, 2005, 32, 1452-8.	2.0	20
40	A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control. International Journal of Rheumatic Diseases, 2013, 16, 532-538.	1.9	19
41	The OMERACT MRI in Arthritis Working Group — Update on Status and Future Research Priorities. Journal of Rheumatology, 2015, 42, 2470-2472.	2.0	18
42	Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the <scp>PREDICT</scp> study. International Journal of Rheumatic Diseases, 2017, 20, 460-468.	1.9	17
43	Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study. Annals of the Rheumatic Diseases, 2018, 77, 1091-1093.	0.9	16
44	Cochrane vertebroplasty review misrepresented evidence for vertebroplasty with early intervention in severely affected patients. BMJ Evidence-Based Medicine, 2020, 25, 85-89.	3.5	16
45	Early vertebroplasty within 3Âweeks of fracture for acute painful vertebral osteoporotic fractures: subgroup analysis of the VAPOUR trial and review of the literature. European Spine Journal, 2020, 29, 1606-1613.	2.2	15
46	Update on Research and Future Directions of the OMERACT MRI Inflammatory Arthritis Group. Journal of Rheumatology, 2011, 38, 2031-2033.	2.0	14
47	Atlas of the OMERACT Heel Enthesitis MRI Scoring System (HEMRIS). RMD Open, 2020, 6, e001150.	3.8	14
48	Magnetic resonance imaging (MRI) of feet demonstrates subclinical inflammatory joint disease in cutaneous psoriasis patients without clinical arthritis. Clinical Rheumatology, 2018, 37, 383-388.	2.2	13
49	Patients with Rheumatoid Arthritis in the Australian OPAL Cohort Show Significant Improvement in Disease Activity over 5 Years: A Multicenter Observational Study. Journal of Rheumatology, 2015, 42, 1603-1609.	2.0	12
50	Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing) Tj ETQq0 0 C subcutaneous TNF inhibitors. Clinical Rheumatology, 2018, 37, 1617-1623.	) rgBT /Ove 2.2	erlock 10 Tf 5 12
51	Vertebroplasty for acute painful osteoporotic fractures (VAPOUR): study protocol for a randomized controlled trial. Trials, 2015, 16, 159.	1.6	11
52	Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population. Rheumatology and Therapy, 2018, 5, 383-401.	2.3	11
53	Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs. Journal of Clinical Rheumatology, 2019, 25, 115-126.	0.9	11
54	Consensus statement on the investigation and management of nonâ€radiographic axial spondyloarthritis (nrâ€ax <scp>S</scp> p <scp>A</scp> ). International Journal of Rheumatic Diseases, 2014, 17, 548-556.	1.9	10

#	Article	IF	CITATIONS
55	Evaluation of Magnetic Resonance Imaging Responsiveness in Active Psoriatic Arthritis at Multiple Timepoints during the First 12 Weeks of Antitumor Necrosis Factor Therapy. Journal of Rheumatology, 2016, 43, 75-80.	2.0	10
56	Utility of Magnetic Resonance Imaging in Diagnosis and Monitoring Enthesitis in Patients with Spondyloarthritis: An OMERACT Systematic Literature Review. Journal of Rheumatology, 2019, 46, 1207-1214.	2.0	10
57	Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset. Journal of Rheumatology, 2020, 47, 1174-1181.	2.0	10
58	The OMERACT Magnetic Resonance Imaging Inflammatory Arthritis Group - advances and priorities. Journal of Rheumatology, 2007, 34, 852-3.	2.0	10
59	Validation of a Knowledge Transfer Tool for the Knee Inflammation MRI Scoring System for Bone Marrow Lesions According to the OMERACT Filter: Data from the Osteoarthritis Initiative. Journal of Rheumatology, 2017, 44, 1718-1722.	2.0	9
60	Consensus statements on the imaging of axial spondyloarthritis in Australia and New Zealand. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 58-69.	1.8	9
61	The OMERACT MRI Inflammatory Arthritis Group: Advances and Future Research Priorities. Journal of Rheumatology, 2009, 36, 1803-1805.	2.0	8
62	Validation of a Knowledge Transfer Tool According to the OMERACT Filter: Does Web-based Real-time Iterative Calibration Enhance the Evaluation of Bone Marrow Lesions in Hip Osteoarthritis?. Journal of Rheumatology, 2017, 44, 1713-1717.	2.0	8
63	Validity and Responsiveness of Combined Inflammation and Combined Joint Damage Scores Based on the OMERACT Rheumatoid Arthritis MRI Scoring System (RAMRIS). Journal of Rheumatology, 2019, 46, 1222-1227.	2.0	8
64	Real-world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia. Clinical Rheumatology, 2022, 41, 53-62.	2.2	7
65	The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice. International Journal of Rheumatology, 2017, 2017, 1-8.	1.6	6
66	Emerging Imaging Techniques in Spondyloarthritis. Rheumatic Disease Clinics of North America, 2020, 46, 287-296.	1.9	6
67	Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naÃ <sup>-</sup> ve patients. Rheumatology, 2022, 61, 1035-1043.	1.9	6
68	Arthritis and enthesitis in the hip and pelvis region in spondyloarthritis - OMERACT validation of two whole-body MRI methods. Seminars in Arthritis and Rheumatism, 2021, 51, 940-945.	3.4	6
69	Reliability and Longitudinal Validity of Computer-assisted Methods for Measuring Joint Damage Progression in Subjects with Rheumatoid Arthritis. Journal of Rheumatology, 2013, 40, 23-29.	2.0	5
70	AC-CUTE: An Open-Label Study to Evaluate Progression of Structural Joint Damage and Inflammation in Subjects with Moderate to Severe Rheumatoid Arthritis. International Journal of Rheumatology, 2018, 2018, 1-9.	1.6	5
71	Questioning the Sensitivity of Magnetic Resonance Imaging in Early Septic Spondylodiscitis. Journal of Clinical Rheumatology, 2001, 7, 184-187.	0.9	4
72	Australian and New Zealand national evidence-based recommendations for the investigation and follow-up of undifferentiated peripheral inflammatory arthritis: an integration of systematic literature research and rheumatological expert opinion. International Journal of Rheumatic Diseases, 2013, 16, 637-651.	1.9	4

#	Article	IF	CITATIONS
73	Percutaneous Vertebroplasty for Acute Painful Osteoporotic Vertebral Fractures—Benefits Shown in VAPOUR Trial Masked When Pooled With Other Clinical Trials. Journal of Bone and Mineral Research, 2019, 34, 1182-1184.	2.8	4
74	Joint and entheseal inflammation in the knee region in spondyloarthritis - reliability and responsiveness of two OMERACT whole-body MRI scores. Seminars in Arthritis and Rheumatism, 2021, 51, 933-939.	3.4	4
75	New applications of imaging techniques for monitoring progression of rheumatoid arthritis and predicting outcome. Imaging in Medicine, 2011, 3, 107-122.	0.0	3
76	Update on the OMERACT Magnetic Resonance Imaging Task Force: Research and Future Directions. Journal of Rheumatology, 2014, 41, 383-385.	2.0	3
77	Criticisms of the VAPOUR trial in a recent commentary are unsubstantiated and incorrect. Evidence-Based Medicine, 2017, 22, 116-117.	0.6	3
78	Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian study. International Journal of Rheumatic Diseases, 2018, 21, 510-516.	1.9	3
79	FRI0140â€EVALUATION OF EFFECTIVENESS AND USAGE PATTERNS OF TOFACITINIB IN TREATMENT OF RHEUMATOID ARTHRITIS IN AUSTRALIA: AN ANALYSIS FROM THE OPAL-QUMI REAL WORLD DATASET. , 2019, , .		3
80	Correspondence on â€~No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related â€~physician-reported spondylitis'?'. Annals of the Rheumatic Diseases, 2023, 82, e187-e187.	0.9	3
81	Magnetic resonance imaging computerized assessment in rheumatoid arthritis: Comment on the article by Goldbach-Mansky et al. Arthritis and Rheumatism, 2004, 50, 1011-1012.	6.7	2
82	Utility of in-office extremity magnetic resonance imaging in rheumatology. Indian Journal of Rheumatology, 2015, 10, 140-146.	0.4	2
83	Vertebroplasty for acute painful osteoporotic fracture. Medical Journal of Australia, 2017, 207, 279-281.	1.7	2
84	Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis. Rheumatology, 2022, , .	1.9	2
85	Vertebroplasty has an important role in managing patients with severe pain when performed early and with appropriate technique. Internal Medicine Journal, 2020, 50, 647-648.	0.8	1
86	Australian Consensus Statements for the Assessment and Management of Non-radiographic Axial Spondyloarthritis. Rheumatology and Therapy, 2022, 9, 1-24.	2.3	1
87	Computerâ€Assisted Image Analysis in Assessment of Peripheral Joint <scp>MRI</scp> in Inflammatory Arthritis: A Systematic Review and Metaâ€analysis. ACR Open Rheumatology, 0, , .	2.1	1
88	Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL. Internal Medicine Journal, 2018, 48, 1185-1192.	0.8	0
89	Imaging in the Mobile Domain. Rheumatic Disease Clinics of North America, 2019, 45, 291-302.	1.9	0
90	P178 The impact of peripheral articular manifestations on the efficacy of ixekizumab in patients with radiographic axial spondyloarthritis. Rheumatology, 2021, 60, .	1.9	0